Humira (Adalimumab) for Psoriasis

Overview:
- Drug Name: Adalimumab
- Brand Name: Humira
- Class: Biologics, specifically a tyrosine kinase inhibitor
- Mechanism: Inhibits tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

Indications
- Approved for:
- Moderate to severe chronic Show Full Answer

Humira (Adalimumab) for Psoriasis

Overview:
- Drug Name: Adalimumab
- Brand Name: Humira
- Class: Biologics, specifically a tyrosine kinase inhibitor
- Mechanism: Inhibits tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.

Indications:
- Approved for:
- Moderate to severe chronic plaque psoriasis
- Active psoriatic arthritis
- Administration:
- Subcutaneous injection
- Available as a pen or prefilled syringe
- Administered every other week

Side Effects:
- Common:
- Respiratory infections
- Headache
- Redness or irritation at injection sites
- Rash
- Rare but Serious:
- Severe infections
- Allergic and hypersensitivity reactions
- Demyelinating disease
- Heart failure
- Lupus-like syndrome
- Increased risk for certain types of cancer, such as lymphoma

Additional Information:
- Combination Therapy: May be prescribed alone or with conventional disease-modifying antirheumatic drugs (DMARDs) like methotrexate.
- FDA Approval: Approved by the U.S. Food and Drug Administration (FDA).

For more details, you can visit the [Humira page on MyPsoriasisTeam](https://www.mypsoriasisteam.com/treatments/humira).

 This AI-generated response comes from MyPsoriasisTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Humira (Adalimumab) for Psoriasis | MyPsoriasisTeam

Adalimumab for Psoriatic Arthritis: How Does It Help? | MyPsoriasisTeam